ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for Its New Sample-to-Answer System, ARIES(TM)

Print | 
Email |  Comment   Share  

Luminex Corporation
12212 Technology Blvd
Austin, TX, 78727

Press release date: May 12, 2014

AUSTIN, Texas - Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff).

"ARIES represents the next generation of sample-to-answer testing, simplifying workflow, and delivering accurate rapid results," said Patrick J. Balthrop, president and chief executive officer of Luminex. "Early detection of group B strep in pregnant women is important to prevent serious disease in infants. Our expanding menu of assays, universal protocol and flexible random batch capability provide unmatched ease of use and versatility for today's laboratories. Every day, we work to develop solutions that advance science and improve health."

Infection with Group B Streptococcus is a leading cause of meningitis, pneumonia, and septicemia in newborns. GBS is a type of bacteria that can cause illness in people of all ages; however, it is the most common cause of some life-threatening infections in newborns. Women colonized with GBS during pregnancy are at increased risk of transmitting the bacteria to their newborn infant during labor and delivery. CDC's guidelines recommend that a pregnant woman be screened for group B strep when she is 35 to 37 weeks pregnant.(1)

ARIES GBS assay will deliver automated, sensitive results faster than culture methods, which can take several days for results and may require sub-culture to detect all strains. The ARIES GBS platform will deliver a streamlined workflow and generate rapid results with little hands-on time.

With a strong track record as an innovator and a leader in molecular diagnostics, Luminex Corporation will soon be the first company to offer multiplexed molecular panels as well as rapid, sample-to-answer testing with the introduction of its new ARIES system and menu of assays.

Luminex is featuring its new ARIES System at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) May 10-13, booth #23 and at the upcoming American Society for Microbiology (ASM), May 17-20 in Boston, Massachusetts, booth #613.

For more information on Luminex products, please visit our website at

About Group B Streptococcus (GBS)

Infection with Group B Streptococcus (GBS), also known as Streptococcus agalactiae, is one of the most important infectious causes of neonatal morbidity and mortality, causing meningitis, pneumonia, and septicemia in the newborns and their mothers. Women vaginally or rectally colonized with GBS during pregnancy are at increased risk of transmitting the bacteria to their newborn infant during labor and delivery. Vaginal GBS colonization has been reported to occur in about 12%-27% of women worldwide.(2)

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit



Luminex Investor Contact
Harriss Currie, 512-219-8020

Sr. Vice President of Finance and CFO

Luminex Media Contact
Mimi Torrington, 512-219-8020

Director of Marketing Communications

Luminex Corporation

Web Site:

Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


Post a comment about this story

(your e-mail address will not be posted)
Comment title:
To submit comment, enter the security code shown below and press 'Post Comment'.

 See related product stories
More .....
 See more product news in:
Chemical Processing and Waste Management
Laboratory and Research Supplies and Equipment
Test and Measuring Instruments
 More New Product News from this company:
Multiplexing Lab Instrument performs up to 50 tests on single sample.
More ....
| Featured Manufacturing Jobs
 Other News from this company:
Luminex Corporation Receives FDA and European Clearance for an Updated Version of Its Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit
Luminex Corporation to Present at Cowen and Company's 31st Annual Health Care Conference
Luminex Corporation to Present at JP Morgan Healthcare Conference
Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story
Search for suppliers of
Sample Conditioning Equipment
Assaying Supplies
Laboratory Equipment & Supplies
Join the forum discussion at:
Tools of the Trade

Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy

Error close

Please enter a valid email address